peripheral vascular News
-
Reva medical announces closing of strategic financing
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing. This funding was led by a global strategic investor with deep experience in medical devices, as well as BioStar Capital, and existing investors. Proceeds from the financing ...
-
Okami Medical Announces FDA 510(k) Clearance of the LOBO-7 and LOBO-9 Vascular Occluders To Address A Wide Range Of Peripheral Embolization Cases
Aliso Viejo, CA – June 7, 2022 – Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LOBO-7 and LOBO-9 Vascular Occluders, the latest addition to the company’s LOBO® Vascular Occlusion ...
-
Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care
Imperative Care, Inc. today announced that it has closed a $260 million Series D financing led by D1 Capital Partners L.P. New investors HealthCor Investments LLC and Innovatus Capital Partners, LLC also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the ...
-
Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease
SAN FRANCISCO, April 2, 2018 – Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced 12-month results from the Phase 1/2 SHIELD trial evaluating SB-030 in patients with peripheral vascular disease undergoing angioplasty. Under an extended trial protocol allowing assessment of secondary endpoint measurements at 12 months following ...
-
OSHwiki article in the spotlight - How to prevent musculoskeletal disorders (MSDs) in the healthcare sector
Musculoskeletal disorders (MSDs) encompass health problems relating to muscles, tendons, the skeleton, cartilage, ligaments, nerves or the peripheral vascular system. They are the leading cause of work-related health problems in the healthcare sector, which accounts for 10 % of the overall workforce in Europe. A new OSHwiki article on the topic explains the scale of the problem, the risk factors ...
-
Okami Medical Announces Major Milestones: FDA 510(k) Clearance and Key Patent for the LOBO Vascular Occluder
Microcatheter-delivered device designed to provide rapid and focal occlusion of a wide range of peripheral arterial targets Aliso Viejo, CA – November 4, 2019 – Okami Medical Inc., a medical device company, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and initial launch of the LOBO™ Vascular Occlusion System. The Company further announced ...
-
£1.1 million project to develop new biodegradable stents
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...
-
Soundbite Medical’s Shock Wave Technology Continues to Crack Through Severe Calcium with the Addition of its First US Site
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, today announced the use of its novel Active Wire 0.014” platform at a first site in the United States in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily ...
-
Imperative Care Appoints Three to Its Board of Directors
Holly Sheffield, Medical Technology Executive and Investment Banker Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader James Rogers, Public and Private Medical Technology Investor Imperative Care, Inc. today announced three appointments to the company’s Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers. “We are grateful to ...
-
TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to develop a unique platform of proprietary ...
By TISSIUM
-
2,000,000 TWO2 Treatments Milestone Reached as TWO2 Study Is Highlighted in Systemic Review of Topical Oxygen Therapies
Advanced Oxygen Therapy Inc. (AOTI) today announced that 2,000,000 treatments of its unique cyclical-pressure Topical Wound Oxygen (TWO2) therapy have now been applied by patients safely at home. Additionally, a high-quality paper published on April 19, 2021 in the journal Diabetic Medicine, entitled Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and ...
-
Okami Medical Announces FDA 510(k) Clearance of the LOBO-5 Vascular Occluder
Aliso Viejo, CA- December 16, 2020 – Okami Medical Inc., a medical device company, today announced the expansion of its LOBO™ Vascular Occlusion System product line with the U.S. FDA 510(k) clearance of the LOBO-5 Vascular Occluder. The LOBO (LOw-profile Braided Occluder) system is uniquely designed to provide interventional physicians with a single-device, ...
-
SoundBite Medical Solutions Announces First Use of its Novel 0.014” Active Wire to Successfully Treat Calcified Below-The-Knee CTOs
Soundbite Medical Solutions Inc. (SBMS) announced today the first use of its novel Active Wire 0.014” platform in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily calcified below-the-knee (BTK) chronic total occlusions (CTO). The procedures were performed by Professor Marianne Brodmann, Head of the Clinical Division of Angiology, Department of ...
-
Stacy Enxing Seng Joins the Vesper Medical Board of Directors
Wayne, PA, January 4, 2021 Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced that Stacy Enxing Seng has joined the board of directors effective immediately. An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional ...
-
Centerline Biomedical Awarded $1.5M Phase II NIH SBIR Grant to Advance Development of Next-Generation IOPS Technology
Centerline Biomedical, Inc. (Centerline) announced on April 21, 2020 the receipt of a Direct to Phase II Small Business Innovation Research (SBIR) grant award from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). This represents the fourth small business grant awarded to the startup founded to commercialize and innovate IOPS™, a novel image guidance ...
-
Okami Medical Announces First Patients Treated With The LOBO Vascular Occluder
ALISO VIEJO, CA, March 5, 2020 — Okami Medical Inc., a medical device company, announced today the successful completion of the first cases with the LOBO™ Vascular Occlusion System. The first offering in the company’s product portfolio, LOBO-3, recently received 510(k) clearance from the U.S. Food and Drug Administration for the occlusion of peripheral arteries. The LOBO ...
-
Expansion of Topical Wound Oxygen (TWO2) Product Family Extends Treatment to Chronic Wound Patients with Larger Limbs, Venous and Diabetic Foot Ulcers
AOTI Inc. announced today an eagerly anticipated expansion of its unique multi-modality Topical Wound Oxygen (TWO2) therapy product family. The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds. Especially ...
-
Instylla announces positive results from preclinical studies of Embrace™ Hydrogel Embolic System in hemorrhage models
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. In a Journal of Vascular and Interventional Radiology (JVIR) publication, Dr. Gandras et al. evaluated[i] the ability of Embrace HES to ...
-
Silk Road Medical Strengthens Leadership Team
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it is strengthening its leadership team with two appointments. William Whealon, Ph.D. has joined the company as Executive Vice President of Research and Development, effective immediately. Silk Road Medical has also named Lucas Buchanan, the company’s ...
-
Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results[i] from the first-in-human clinical trial of Embrace™ Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR). This prospective, single-arm ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you